Osteopore Launches Trial at Queensland Children’s Hospital for Cleft Lip Kids
Osteopore and QCH launch clinical trial targeting children with unilateral cleft lip
Osteopore Limited (ASX: OSX) and Queensland Children’s Hospital (QCH) have launched and commenced a clinical trial for paranasal augmentation in paediatric patients with unilateral cleft lip. Paranasal augmentation refers to the correction of the nose and surrounding upper jaw structure, and the single-arm feasibility trial will enrol up to 5 paediatric patients, with 3 already recruited and the first treatment scheduled for July 2026.
The study is led by Dr. Yun Phua, a Plastic and Reconstructive Surgeon at QCH and Mater Hospital. Notably, this is the second paediatric study led by Dr. Phua at QCH — the first addressed temporal hollowing in children and was announced on 23 May 2025 — signalling a deepening institutional relationship between Osteopore and one of Australia’s leading children’s hospitals.
Trial fast facts:
- Patients recruited to date: 3 of 5
- Lead surgeon: Dr. Yun Phua, QCH and Mater Hospital
- First patient treatment: July 2026
- Full recruitment expected: End of 2026 / June 2027
- Follow-up period: 12 months post-surgery per patient
- Outcomes tool: Cleft-Q validated patient-reported outcome measure
When big ASX news breaks, our subscribers know first
Why this trial matters — the clinical and commercial case
The problem with current standard of care
The existing standard treatment for paranasal deficiency in cleft lip patients is cancellous bone grafting harvested from the hip. This approach is associated with poor long-term graft retention and unpredictable outcomes for nasal form, meaning many patients require revision surgeries without achieving consistent facial symmetry.
Osteopore’s medical-grade polycaprolactone-tricalciumphosphate (mPCL-TCP) scaffold is designed to replace this graft entirely. The company says the implant provides a structurally accurate, reproducible alternative that supports bone regeneration and nasal base support without adding surgical time. Outcomes being measured include facial symmetry, the rate of revision surgeries, and overall quality of life, all assessed using the validated Cleft-Q patient-reported outcome tool.
The technology behind the implant
Osteopore’s bioresorbable scaffold is 3D printed from mPCL-TCP, a composite material that gradually degrades as the body regenerates bone. Throughout the healing process, the scaffold mimics the mechanical properties of trabecular bone (the spongy inner layer of bone tissue), providing structural support while natural bone formation takes place. Once healing is complete, the scaffold is resorbed and replaced by the patient’s own tissue.
Each implant is designed using the individual patient’s CT imaging data and manufactured under Osteopore’s established Patient Specific Implant (PSI) workflow. Critically for investors, this workflow is not experimental at QCH — it is already in clinical use at the hospital, which materially reduces execution risk for this trial.
Dr. Yun Phua, Plastic and Reconstructive Surgeon, QCH
“This trial gives us the opportunity to offer something truly personalised: an implant designed specifically for each child’s anatomy that corrects the deformity and, over time, becomes their own tissue. I am excited to lead this work and hopeful it will set a new standard of care for cleft patients.”
A USD 1.9 billion market opportunity in paediatric reconstructive medicine
Cleft lip and palate affects approximately 1 in 1,000 births globally, making it one of the most prevalent congenital conditions worldwide. Patients typically undergo multiple reconstructive procedures throughout childhood and adolescence, creating a recurring demand for effective, durable surgical solutions.
The global cleft lip and palate repair market is sizeable and growing, driven by rising surgical volumes, increasing awareness of treatment options, and the adoption of advanced biomaterials.
| Metric | Value (USD) | Value (AUD approx.) | Notes |
|---|---|---|---|
| 2024 market value | USD 1.2 billion | ~AUD 1.7 billion | — |
| 2033 forecast | USD 1.9 billion | ~AUD 2.7 billion | CAGR 5.5% |
According to the announcement, this trial, conducted at one of Australia’s leading children’s hospitals, provides a “strong clinical and commercial foundation for broader market adoption.” For investors, the trial serves as both a clinical validation event and a direct entry point into an addressable market approaching USD 2 billion by 2033.
CEO Dr. Yujing Lim
“This trial positions us at the forefront of a global market opportunity worth nearly USD 2 billion, and is precisely why we exist as a company — to engineer better outcomes for patients and create lasting value for our shareholders.”
The next major ASX story will hit our subscribers first
Timeline and what investors should watch
With active recruitment underway and the first treatment approaching, investors have a series of concrete milestones to monitor over the next two years. The progression of Cleft-Q outcome data collection will be a particularly important validation point, as it will determine whether Osteopore’s scaffold delivers measurably superior results against the current standard of care.
- July 2026 — First patient treatment
- End of 2026 — Full patient recruitment (up to 5 patients)
- June 2027 — Patient recruitment completion deadline
- 12 months post-surgery — Follow-up data collection per patient
- Ongoing — Outcomes assessed via validated Cleft-Q tool
Taken alongside the temporal hollowing study announced in May 2025, this second QCH trial under Dr. Phua points to a broader pattern of expanding clinical validation across paediatric indications. Two concurrent studies at the same institution, under the same lead surgeon, suggest growing confidence in Osteopore’s PSI workflow and a strengthening partnership with one of Australia’s most recognised children’s hospitals.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.